Anti-Human CD137 (4-1BB) (Urelumab)

This biosimilar antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.

Liquid

Recombinant biosimilar antibodies are manufactured in an animal free facility using only in vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.

To protect mouse colonies from infection by pathogens and to assure that experimental preclinical data is not affected by such pathogens, all of Leinco’s recombinant biosimilar antibodies are tested and guaranteed to be negative for all pathogens in the IDEXX IMPACT I Mouse Profile.

Functional grade biosimilar antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles.

Research Use Only

2 – 8° C Wet Ice

This non-therapeutic biosimilar antibody uses the same variable region sequence as the therapeutic antibody Urelumab. BMS-66513 (urelumab) specifically targets and binds to CD137.

CD137, also known as 4-1BB or TNFRSF9, is a member of the tumor necrosis factor receptor (TNFR) superfamily. It is a type I transmembrane protein expressed on the surface of activated T cells, natural killer (NK) cells, dendritic cells, and other immune cells. CD137 functions as a co-stimulatory molecule, enhancing T cell proliferation, survival, and cytokine production upon binding to its ligand, CD137L. This interaction plays a crucial role in immune responses, making CD137 an attractive target for cancer immunotherapy^1-3.

BMS-66513, also known as urelumab, is a humanized IgG4 monoclonal antibody that acts as an agonist for CD137. By binding to CD137, urelumab enhances the activation and proliferation of T-cells and NK cells, leading to increased antitumor activity. It has shown potential in potentiating tumor cell killing and enhancing the cytotoxicity of other therapeutic antibodies like rituximab. Urelumab is being investigated for its efficacy in treating various solid tumors and hematological malignancies^4-6.

CD137 is expressed on the surface of activated T cells, NK cells, dendritic cells, and other immune cells.

TNFSF9/4-1BBL, TRAF1, TRAF2, TRAF3

1. Glorieux C, Huang P. Cancer Communications. 2019;39(1):70.
2. CD137 in NK cells | Blood | American Society of Hematology. Accessed August 11, 2024. https://ashpublications.org/blood/article/115/15/2987/26866/CD137-in-NK-cells
3. Circulating CD137+ T Cells Correlate with Improved Response to Anti-PD1 Immunotherapy in Patients with Cancer | Clinical Cancer Research | American Association for Cancer Research. Accessed August 11, 2024. https://aacrjournals.org/clincancerres/article/28/5/1027/681690/Circulating-CD137-T-Cells-Correlate-with-Improved
4. Urelumab. Accessed August 11, 2024. https://go.drugbank.com/drugs/DB12077
5. Chester C, Sanmamed MF, Wang J, Melero I. Blood. 2018;131(1):49-57.
6. Khushalani NI, Ott PA, Ferris RL, et al. J Immunother Cancer. 2024;12(3):e007364.
7. Anti-Human 4-1BB Recombinant Antibody (Urelumab) - Creative Biolabs. Accessed August 18, 2024. https://www.creativebiolabs.net/Anti-Human-4-1BB-Therapeutic-Antibody-Urelumab-13548.htm